शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSELACTOSE (INDIA) LTD.· Pharmaceuticals & BiotechnologyMinimalNeutral
Announced Wed, 14 Oct, 2026 · 15:42 IST

Quarterly demat compliance certificate submitted to BSE

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.0%Reaction day
₹102.05
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+1.7% vs market
Pharmaceuticals peers, median of 172sector-0.6%+0.7% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.0-1.6+1.7-0.6+0.7
Next day
+3.9-1.0+4.8-0.7+4.6
2d
-1.0-2.6+1.6-1.9+0.9
3d
+3.9-5.1+9.0-3.5+7.4
4d
-2.5-6.1+3.6-4.4+1.9
5d
-2.5-8.3+5.8-6.1+3.6
1w
-1.0-6.4+5.3-2.9+1.8
15d
+0.0pendingpending-1.1+1.1
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lactose India has filed the Regulation 74(5) compliance certificate for the quarter ended 30 September 2026. The company's Registrar and Share Transfer Agent, Bigshare Services, has confirmed to BSE that all securities received from depository participants for dematerialization were processed, and physical certificates have been cancelled and the depository name substituted as registered owner in the member register within 15 days. This is a standard SEBI-mandated quarterly filing.

Likely market impact

Routine compliance filing with no material effect on shareholders or stock price.